Persistent intraprostatic androgen concentrations after medical castration in healthy men.
about
Emerging mechanisms of resistance to androgen receptor inhibitors in prostate cancerAbiraterone in the management of castration-resistant prostate cancer prior to chemotherapyAbiraterone in the treatment of metastatic castration-resistant prostate cancerIntraprostatic testosterone and dihydrotestosterone. Part I: concentrations and methods of determination in men with benign prostatic hyperplasia and prostate cancerAndrogens and prostate diseaseModulation of Androgen Receptor Activation Function 2 by Testosterone and DihydrotestosteroneIntraprostatic testosterone and dihydrotestosterone. Part II: concentrations after androgen hormonal manipulation in men with benign prostatic hyperplasia and prostate cancer.Hedgehog Proteins Consume Steroidal CYP17A1 Antagonists: Potential Therapeutic Significance in Advanced Prostate CancerAbiraterone and increased survival in metastatic prostate cancerProstate cancer progression and metastasis: potential regulatory pathways for therapeutic targeting.Castration resistance in human prostate cancer is conferred by a frequently occurring androgen receptor splice variant.Expression of SLCO transport genes in castration-resistant prostate cancer and impact of genetic variation in SLCO1B3 and SLCO2B1 on prostate cancer outcomes.Targeted androgen pathway suppression in localized prostate cancer: a pilot study.Redefining hormone resistance in prostate cancer.Effects of testosterone on the lower urinary tract go beyond the prostate: New insights, new treatment options.The transcriptomics of de novo androgen biosynthesis in prostate cancer cells following androgen reductionThe impact of point mutations in the human androgen receptor: classification of mutations on the basis of transcriptional activityMDV3100 for the treatment of prostate cancer.Novel drugs targeting the androgen receptor pathway in prostate cancer.Relationship Between Second to Fourth Digit Ratios and Benign Prostatic Hyperplasia in Aging MenDihydrotestosterone administration does not increase intraprostatic androgen concentrations or alter prostate androgen action in healthy men: a randomized-controlled trial.New hormonal therapies for castration-resistant prostate cancer.Novel Androgen Deprivation Therapy (ADT) in the Treatment of Advanced Prostate CancerResistance to CYP17A1 inhibition with abiraterone in castration-resistant prostate cancer: induction of steroidogenesis and androgen receptor splice variants.Intratumoral de novo steroid synthesis activates androgen receptor in castration-resistant prostate cancer and is upregulated by treatment with CYP17A1 inhibitors.Mechanisms mediating androgen receptor reactivation after castration.Efficacy and safety of gonadotropin-releasing hormone agonists used in the treatment of prostate cancer.Impact of male hormonal contraception on prostate androgens and androgen action in healthy men: a randomized, controlled trial.An update on androgen deprivation therapy for prostate cancer.Minireview: Androgen metabolism in castration-resistant prostate cancer.Maintenance of intratumoral androgens in metastatic prostate cancer: a mechanism for castration-resistant tumor growth.Distinct patterns of dysregulated expression of enzymes involved in androgen synthesis and metabolism in metastatic prostate cancer tumors.Androgen receptor functions in castration-resistant prostate cancer and mechanisms of resistance to new agents targeting the androgen axisStable Intraprostatic Dihydrotestosterone in Healthy Medically Castrate Men Treated With Exogenous Testosterone.Oxidative DNA damage in the prostate may predispose men to a higher risk of prostate cancer.Intracrine androgen metabolism in prostate cancer progression: mechanisms of castration resistance and therapeutic implicationsAndrogen receptor: role and novel therapeutic prospects in prostate cancer.Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue.Preoperative therapy for localized prostate cancer: a comprehensive overview.Castration-resistant prostate cancer: targeting androgen metabolic pathways in recurrent disease.
P2860
Q26777310-EE9C53EA-D34B-4B7F-A13A-528D13CAC285Q26786543-0B0CC992-385D-46D6-8F76-6FCBE8100F44Q26853635-13058781-A248-4BFD-BC6C-DB7F9C2D5C22Q27005840-BFB1E4FB-04DC-4C7B-9FEB-6DAB5D0A4234Q27010093-C87D346F-93A2-49AC-AC34-E71AE2DAF5D8Q27646416-C7D478A4-6A12-4A6C-82F3-98D6396C1A4AQ27690719-ECB3EC88-A7D3-4741-97F0-0BDB0FB794C5Q28277254-42BE4B24-0251-40C5-AD7A-ABA9711F9181Q29617512-60451D6B-1DCA-47A2-A35B-9616CCAF0F0BQ30409623-74F80827-42DC-40AD-ADDA-84EA5D286424Q30495758-360D22A6-A516-4534-929B-1FD098EE230BQ30499412-C6086692-4266-4CAF-B725-ACFA7D84A9BDQ30563985-2FF88B17-BF25-4387-877E-0307289DFD86Q33903836-B214A0B7-727A-4232-9295-65ADCE02F22DQ34114694-78323DFB-7A78-4FD8-A724-359655BF004EQ34127128-DD40021D-B2DC-491B-9FEB-4A3055FFF4C3Q34189517-D1DD2466-EEB7-442C-A8FA-D231A898797FQ34245740-04A0C6BE-7D17-45C1-9FF2-EE2810139DEDQ34395777-CE499BCE-6085-4B16-8CE4-A6E3ED52D8FAQ34484103-D205107E-8B12-4498-AE9D-75449BCE1CB0Q34622506-F476EE75-9A0D-47B3-9BB3-DD879DC8B94CQ35196715-318689BA-BA4C-40E7-8B4E-3F99AE4A32A5Q35210730-51C310A9-69DA-4882-84BE-4F3B040CCC15Q35249697-C4F6AAD8-F869-4188-9744-B7E8167491E3Q35532230-240443F2-4DFE-475D-AF67-3B0FC4B632E8Q35633454-B8CB9212-013B-43B9-BE7F-E9D29CE462BBQ35689824-E6A2E9EA-6366-41DE-9CCA-34492867F301Q36134782-6B0AEC54-E33A-4B42-B4AC-8A54D688A8A1Q36289952-3BD907D4-E905-4447-B120-7B05EBAB24A0Q36789277-3797B03A-CD0B-4C53-9655-CE3CF338794DQ36876865-C33EB7A3-271D-49AC-8698-C61324FDBFFCQ36937170-C53AAE37-A2A0-408A-8D1C-4F1FFFCD6903Q36961208-CFFA49C7-B69F-44BC-8421-0CE1CCEFC612Q37057953-90455A1D-2A19-4F46-90E4-A675701AFD5DQ37109463-24C35B7B-FD2B-4490-868F-52CE911C4BCAQ37159878-DC773834-947F-45FF-903D-26BFFAA50AC1Q37256846-130B3395-F64B-4DBD-8BB5-60A18C729CECQ37304966-0FCE9B86-A6D5-4235-9270-FDD4393DAAE0Q37354526-4D7B7D1B-7B16-4F86-9621-7C0F0E04CCC8Q37469444-33AF8FC0-3D02-4843-A14D-19A3C9708780
P2860
Persistent intraprostatic androgen concentrations after medical castration in healthy men.
description
2006 nî lūn-bûn
@nan
2006 թուականի Օգոստոսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի օգոստոսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年学术文章
@wuu
2006年学术文章
@zh-cn
2006年学术文章
@zh-hans
2006年学术文章
@zh-my
2006年学术文章
@zh-sg
2006年學術文章
@yue
name
Persistent intraprostatic andr ...... cal castration in healthy men.
@ast
Persistent intraprostatic andr ...... cal castration in healthy men.
@en
Persistent intraprostatic andr ...... cal castration in healthy men.
@nl
type
label
Persistent intraprostatic andr ...... cal castration in healthy men.
@ast
Persistent intraprostatic andr ...... cal castration in healthy men.
@en
Persistent intraprostatic andr ...... cal castration in healthy men.
@nl
prefLabel
Persistent intraprostatic andr ...... cal castration in healthy men.
@ast
Persistent intraprostatic andr ...... cal castration in healthy men.
@en
Persistent intraprostatic andr ...... cal castration in healthy men.
@nl
P2093
P356
P1476
Persistent intraprostatic androgen concentrations after medical castration in healthy men
@en
P2093
Alvin M Matsumoto
Daniel W Lin
David L Hess
Elahe A Mostaghel
Lawrence D True
Peter S Nelson
Stephanie T Page
William J Bremner
P304
P356
10.1210/JC.2006-0968
P407
P50
P577
2006-08-01T00:00:00Z